Breaking Down the Barriers to PCSK9 Inhibitor Use in Clinically Appropriate Patients: Bringing the Team Together to Improve Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

The Role of PCSK9 Inhibitors in Lowering LDL-C in Patients with Dyslipidemia: What Managed Care Needs to Know is a 3-part live webinar series that will provide attendees with the latest information in Dyslipidemia

Part 3 of this series focuses on strategies for identifying patients and appropriately
utilizing PCSK9 inhibitors in dyslipidemia management.

This activity is an archive from the webinar held June 13, 2018

If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This program is supported by educational grants from
Amgen and Sanofi US and Regeneron Pharmaceuticals.

Description:
LDL-C is a major factor in the development of cardiovascular disease (CVD) which effects over 73 million adults in the United States. It is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Recent studies have begun debates among healthcare professionals about how best to measure LDL in order to identify patients at high risk for CVD and individualize therapy for them. Another area of intense interest is whether directing treatment to additional lipid targets will reduce the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins which inhibit the liver's production of LDL cholesterol in the first place, and to which some patients don't respond well. Recent data has shown that these PCSK9 agents cut levels of LDL cholesterol by close to 70 percent, more than statins alone.

Upon Completion of this activity, participants will be able to:

  • Implement current evidence to identify patient populations that are expected to derive the greatest benefit from non-statin therapies

  • Describe “statin intolerance” and “statin failure” and appropriate treatment options for patients with either of these conditions

  • Examine current evidence for the optimal LDL-C goal for patients with dyslipidemia

  • Address barriers to appropriate evidence-based use of PCSK9 inhibitors among the entire healthcare team
     

Faculty: Steven E. Nissen, MD, MACC
Professor of Medicine
The Cleveland Clinic School of Medicine
Cardiovascular Medicine
Department Chair
Cleveland Clinic Main Campus

Disclosure:

Dr. Nissen has received grants for clinical research from Amgen, AstraZeneca, Daiichi-Sankyo, Eli Lilly, Medical Research Institute, Novartis, Novo Nordisk, Omthera Pharmaceuticals, Orexigen, Pfizer, Resverlogix, Roche, Sanofi-Aventis, Southern Australian Health, and Vivus. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This program is supported by educational grants from
Amgen and Sanofi US and Regeneron Pharmaceuticals.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue